Type 1 diabetes (T1D) is one of the most prevalent chronic diseases. The disease places a lifelong burden on the patient and the immediate family and triggers significant societal costs.
Preventive therapies under development require detection of individuals at risk of developing T1D through screening for biomarkers. Establishing screening programs is a critical task and currently constitutes a bottleneck for the identification of persons at risk and thus also for the development of new drugs.
A major reason why screening for T1D is not yet common is the ethical issue of screening for a disease that cannot be cured. But with the advent of drugs that can delay the diagnosis, the case may be different. We take this debate between patients, ethicists, researchers, politicians and industry.
Jesper Johannesen, professor, Steno Diabetes Center Copenhagen
Karen-Helene Hjort, News host, TV 2
Mayor of Health and Care, Københavns Kommune, Sisse Marie Welling
Professor of ethics, Thomas Søbirk Petersen
DiaLab (Dansk Erhverv) chairman Henrik Christensen
The Danish Diabetes Association, head of research Tanja Thybo
Type 1 Think tank for diabetes, chairwoman Tine Filges
Professor, Steno Diabetes Center Copenhagen, Jesper Johannesen